Balance of neutralizing Antibodies and Antibody Dependent Enhancement (ADE) In Dengue Virus (DENV) infection: a literature review
Abstract
Dengue fever is a major public health concern worldwide, especially in regions with warm temperatures. Dengue Virus (DENV) from Flaviviridae, which has 4 serotypes DENV-1, DENV-2, DENV-3, and DENV-4) caused Dengue. DENV can cause three different types of dengue fever: Classical DF, DHF, and DSS. To fight off DENV infection, the body will produce an immunological response. Neutralizing antibodies are one of the immune responses that play a role in preventing viral infections. However, antibodies can also contribute to DENV infection severity through a process called Antibody Dependent Enhancement (ADE). The amount of antibodies bound to virus particles is related to viral neutralization and ADE. Neutralization occurs when antibody concentrations exceed the stoichiometric threshold and when antibody concentrations are higher than the minimal amount that is required for stable attachment of virions to cells. ADE occurs in the presence of antibodies below the stoichiometric threshold for neutralization and less than the minimal amount required for stable attachment of viral particles to cells. Antibody binding stoichiometry is determined by the affinity of the antibody and the number of epitopes that can bind to the virion. According to scholarly discourse, it is commonly held that the balance between neutralizing antibodies and ADE can be influenced by two contexts, namely the affinity and amount of antibodies.
Keywords
References
A, V. L., Leslie, G., & C, P. T. (2016). Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiology and Molecular Biology Reviews, 80(4), 989–1010. https://doi.org/10.1128/MMBR.00024-15
Abbas A, Litchman A, P. S. (2019). Basic Immunonogy- Functions and Disorders of the Immune System.
Centre for Disease Control and Prevention. (n.d.). Data and Maps. Retrieved December 7, 2022, from https://www.cdc.gov/dengue/statistics-maps/data-and-maps.html
Centre for Disease Control and Prevention. (2022). About Dengue. Department of Health & Human Services. https://www.cdc.gov/dengue/about/index.html
de Alwis, R., Williams, K. L., Schmid, M. A., Lai, C.-Y., Patel, B., Smith, S. A., Crowe, J. E., Wang, W.-K., Harris, E., & de Silva, A. M. (2014). Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathogens, 10(10), e1004386–e1004386. https://doi.org/10.1371/journal.ppat.1004386
Dowd, K. A., & Pierson, T. C. (2011). Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology, 411(2), 306–315. https://doi.org/10.1016/j.virol.2010.12.020
European Centre for Disease Control and Prevention. (n.d.). Dengue Worldwide Overview. Retrieved February 5, 2023, from https://www.ecdc.europa.eu/en/dengue-monthly
Guzman, M. G., Alvarez, M., Rodriguez-Roche, R., Bernardo, L., Montes, T., Vazquez, S., Morier, L., Alvarez, A., Gould, E. A., Kouri, G., & Halstead, S. B. (2007). Neutralizing antibodies after infection with dengue 1 virus. Emerging Infectious Diseases, 13(2), 282–286. https://doi.org/10.3201/eid1302.060539
Guzman, M. G., Halstead, S. B., Artsob, H., Buchy, P., Farrar, J., Gubler, D. J., Hunsperger, E., Kroeger, A., Margolis, H. S., Martínez, E., Nathan, M. B., Pelegrino, J. L., Simmons, C., Yoksan, S., & Peeling, R. W. (2010). Dengue: a continuing global threat. Nature Reviews Microbiology, 8(12), S7–S16. https://doi.org/10.1038/nrmicro2460
Guzmán, M. G., Kourí, G., Martínez, E., Bravo, J., Riverón, R., Soler, M., Vázquez, S., & Morier, L. (1987). Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ, 21(3), 270–279. https://www.ncbi.nlm.nih.gov/pubmed/3442718
Guzman, M. G., & Vazquez, S. (2010). The complexity of antibody-dependent enhancement of dengue virus infection. Viruses, 2(12), 2649–2662. https://doi.org/10.3390/v2122649
Halstead, S. B. (2016). Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. The American Society of Tropical Medicine and Hygiene, 95(4), 741–745. https://doi.org/10.4269/ajtmh.16-0222
Hasan, S., Jamdar, S. F., Alalowi, M., & Al Ageel Al Beaiji, S. M. (2016). Dengue virus: A global human threat: Review of literature. Journal of International Society of Preventive & Community Dentistry, 6(1), 1–6. https://doi.org/10.4103/2231-0762.175416
Kotaki, T., Kurosu, T., Grinyo-Escuer, A., Davidson, E., Churrotin, S., Okabayashi, T., Puiprom, O., Mulyatno, K. C., Sucipto, T. H., Doranz, B. J., Ono, K., Soegijanto, S., & Kameoka, M. (2021). An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency. Scientific Reports, 11(1), 12987. https://doi.org/10.1038/s41598-021-92403-9
Langerak, T., Mumtaz, N., Tolk, V. I., van Gorp, E. C. M., Martina, B. E., Rockx, B., & Koopmans, M. P. G. (2019). The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis. PLoS Pathogens, 15(4), e1007640–e1007640. https://doi.org/10.1371/journal.ppat.1007640
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020). Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nature Microbiology, 5(10), 1185–1191. https://doi.org/10.1038/s41564-020-00789-5
Lok, S.-M., Kostyuchenko, V., Nybakken, G. E., Holdaway, H. A., Battisti, A. J., Sukupolvi-Petty, S., Sedlak, D., Fremont, D. H., Chipman, P. R., Roehrig, J. T., Diamond, M. S., Kuhn, R. J., & Rossmann, M. G. (2008). Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nature Structural & Molecular Biology, 15(3), 312–317. https://doi.org/10.1038/nsmb.1382
Luo, Y., Guo, X., Yan, H., Fang, D., Zeng, G., Zhou, J., & Jiang, L. (2015). Comprehensive mapping infection-enhancing epitopes of dengue pr protein using polyclonal antibody against prM. Applied Microbiology and Biotechnology, 99(14), 5917–5927. https://doi.org/10.1007/s00253-015-6538-9
McGill Journal of Global Health. (2022). Did Dengvaxia-associated deaths result in an increase in vaccine hesitancy in the Philippines. https://mghjournal.com/2020/09/29/vol-ix-did-dengvaxia-associated-deaths-result-in-an-increase-in-vaccine-hesitancy-in-the-philippines/
Payne, S. (2023). 6 - Immunity and resistance to viruses (S. B. T.-V. (Second E. Payne (ed.); pp. 73–88). Academic Press. https://doi.org/https://doi.org/10.1016/B978-0-323-90385-1.00016-9
Prevention, C. for D. C. (2022). Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices. https://www.cdc.gov/mmwr/volumes/70/rr/rr7006a1.htm#:~:text=Vaccinating Seronegative Children,seronegative person misclassified as seropositive
R., T. M., M., S. D., B., P. P., & B., S. R. (2018). EMERGING THERAPY FOR DENGUE. International Journal of Current Pharmaceutical Research, 10(2), 1–4. https://doi.org/10.22159/ijcpr.2018v10i2.25848
Roehrig, J. T., Bolin, R. A., & Kelly, R. G. (1998). Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica. Virology, 246(2), 317–328. https://doi.org/https://doi.org/10.1006/viro.1998.9200
Rothman, A. L. (2011). Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature Reviews Immunology, 11(8), 532–543. https://doi.org/10.1038/nri3014
Sarker, A., Dhama, N., & Gupta, R. D. (2023). Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1200195
Shukla, R., Ramasamy, V., Shanmugam, R. K., Ahuja, R., & Khanna, N. (2020a). Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. Frontiers in Cellular and Infection Microbiology, 10. https://www.frontiersin.org/articles/10.3389/fcimb.2020.572681
Shukla, R., Ramasamy, V., Shanmugam, R. K., Ahuja, R., & Khanna, N. (2020b). Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. Frontiers in Cellular and Infection Microbiology, 10. https://doi.org/10.3389/fcimb.2020.572681
Souza, L. R., Colonna, J. G., Comodaro, J. M., & Naveca, F. G. (2022). Using amino acids co-occurrence matrices and explainability model to investigate patterns in dengue virus proteins. BMC Bioinformatics, 23(1), 80. https://doi.org/10.1186/s12859-022-04597-y
Tirado, S. M. C., & Yoon, K.-J. (2003). Antibody-Dependent Enhancement of Virus Infection and Disease. Viral Immunology, 16(1), 69–86. https://doi.org/10.1089/088282403763635465
Wilder-Smith, A., Hombach, J., Ferguson, N., Selgelid, M., O’Brien, K., Vannice, K., Barrett, A., Ferdinand, E., Flasche, S., Guzman, M., Novaes, H. M., Ng, L.-C., Smith, P. G., Tharmaphornpilas, P., Yoon, I.-K., Cravioto, A., Farrar, J., & Nolan, T. M. (2019). Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. The Lancet Infectious Diseases, 19(1), e31–e38. https://doi.org/10.1016/s1473-3099(18)30494-8
World Health Organization. (n.d.). Dengue and severe dengue. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
Xu, M., Zuest, R., Velumani, S., Tukijan, F., Toh, Y. X., Appanna, R., Tan, E. Y., Cerny, D., MacAry, P., Wang, C.-I., & Fink, K. (2017). A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus. Npj Vaccines, 2(1), 2. https://doi.org/10.1038/s41541-016-0003-3
DOI: 10.24815/jks.v24i3.34142
Refbacks
- There are currently no refbacks.